Drug intelligence / Profile preview

GO-L100

Development stage: Preclinical
Lead developer: GO Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

GO-L100 is a monoclonal antibody therapeutic candidate developed by GO Therapeutics. It is designed to target truncated O-glycans, specifically the Tn (GalNAc-alpha-Ser/Thr) and STn (Sialyl-Tn) antigens, which are tumor-associated carbohydrate antigens (TACAs). These antigens arise from aberrant glycosylation processes in malignant cells and are highly specific to tumors, being virtually absent in healthy adult tissues. GO-L100 is specifically being developed for the treatment of all types of breast cancer. By targeting these 'super-clean' antigens, the drug aims to provide a highly selective therapeutic option with a reduced risk of off-target toxicity.

Targets

STn-MUC1 (Sialyl-Tn-MUC1)Tn (Tn antigen)

Beyond the preview

Go deeper on GO-L100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GO-L100.

Explore the full profile